<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095393</url>
  </required_header>
  <id_info>
    <org_study_id>RA0005</org_study_id>
    <nct_id>NCT01095393</nct_id>
  </id_info>
  <brief_title>National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)</brief_title>
  <official_title>National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia®) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Data Bank for Rheumatic Diseases (NDB)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational registry to assess the longer-term risk of serious infections and malignancies
      reported with TNFα-blocker therapy, as well as the longer-term risk of cardiovascular and
      thromboembolic events in adult Rheumatoid Arthritis (RA) patients treated with Cimzia® as
      compared to non-biologic DMARD-treated controls.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with lymphoma</measure>
    <time_frame>6 years</time_frame>
    <description>Number of participants with lymphoma during the observational period (up to 6 years)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious infections</measure>
    <time_frame>6 years</time_frame>
    <description>Number of participants with serious infections during the observational period (up to 6 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with non-lymphoma malignancies</measure>
    <time_frame>6 years</time_frame>
    <description>Number of participants with non-lymphoma malignancies during the observational period (up to 6 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with cardiovascular events</measure>
    <time_frame>6 years</time_frame>
    <description>Number of participants with cardiovascular events during the observational period (up to 6 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with thromboembolic events</measure>
    <time_frame>6 years</time_frame>
    <description>Number of participants with thromboembolic events during the observational period (up to 6 years)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">12500</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Certolizumab pegol (CZP)</arm_group_label>
    <description>Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-biologic DMARD</arm_group_label>
    <description>Subjects with RA receiving treatment with non-biologic DMARD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatologist referral or patient direct enrollment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RA and started treatment with certolizumab pegol (Cimzia®; CZP) or non-biologic DMARD
             within the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick Wolfe, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>National Data Bank for Rheumatic Disease</affiliation>
  </overall_official>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Certolizumab Pegol</keyword>
  <keyword>CZP</keyword>
  <keyword>Cimzia®</keyword>
  <keyword>NDB</keyword>
  <keyword>registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

